Does amiloride modify the increased urine output that occurs with lithium treatment in individuals with a mood disorder?

Phase 4

Completed

• Conditions: ithium induced nephrogenic diabetes insipidus; Lithium induced nephrogenic diabetes insipidus; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12610000428066
• Lead Sponsor: Health Research Council of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Inclusion criteria.
All patients aged 18 to 60, with a bipolar or unipolar affective disorder requiring the commencement of lithium to manage their psychiatric disorder, and who are able to give informed consent.

Exclusion Criteria

Exclusion criteria.
Any individual who is unable to give informed consent.
Any patients with evidence of renal impairment (plasma creatinine > 0.12 mmol/l)
Any patient unable to comply with a fluid restriction.
Any previous exposure to lithium
Pregnancy, thyroid disease.
Any contraindication to amiloride.
Thiazide or Angiotensin converting enzyme inhibitors, requirement for potassium supplements.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modification of urinary concentrating ability and associated changes in urinary aquaporin excretion.<br>Urinary concentrating ability is assessed using a standard overnight water deprivation study with the morning urine collected and urine osmolaity measured. This is then followed by the adminstration of desmopressin (dDAVP - synthetic anti-diuretic hormone) intra-nasally and urine samples collected at 2,4, and 6hours to measure maximal urine osmolality.[Baseline and 6 weeks after each treatment. A total of 4 time points.];Urine aquaporin 2 (AQP2) concentration is measured at the same time points using an in house immunoassay.[Baseline and 6 weeks after each treatment. A total of 4 time points.]

Secondary Outcome Measures

Name	Time	Method
one[Nil]